{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual time to response for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0.7"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"0.7","value":"0.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Time to response is defined as the time interval (in months) from T-cell infusion to initial date of documented confirmed response (PR or better) in the subset of participants who showed a confirmed BOR of PR or better by Investigator assessment per IMWG (2016).","dispersionType":"Full Range","groups":[{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.","id":"OG000","title":"GSK3377794"},{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.","id":"OG001","title":"GSK3377794+Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Modified ITT Population. Only those participants with a confirmed response per IMWG 2016 were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 108 weeks","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"Months"}